Agilent Technologies, Inc. (A)
148.32
-0.94
(-0.63%)
USD |
NYSE |
Dec 04, 16:00
148.50
+0.18
(+0.12%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 41.98B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 6.64% |
| Valuation | |
| PE Ratio | 32.45 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.089 |
| Price to Book Value | 6.228 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.255 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4976 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 43.19% |
Profile
| Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. |
| URL | http://www.agilent.com |
| Investor Relations URL | https://www.investor.agilent.com/overview/default.aspx |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 24, 2025 |
| Next Ex-Dividend Date | Jan. 06, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |
Ratings
Profile
| Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. |
| URL | http://www.agilent.com |
| Investor Relations URL | https://www.investor.agilent.com/overview/default.aspx |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 24, 2025 |
| Next Ex-Dividend Date | Jan. 06, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |